No Data
No Data
Guangdong Zhongsheng Pharmaceutical (002317.SZ) has not yet laid out in the field of cellular immunotherapy.
Guangdong Zhongsheng Pharmaceutical (002317.SZ) stated on the investor interaction platform on August 6 that the company has not yet established a layout in cellular immunotherapy.
Guangdong Zhongsheng Pharmaceutical (002317.SZ): Its holding subsidiary has obtained the ethical approval for the phase II clinical trial of the class I innovative drug Oladiravir granules.
Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced on August 2nd that its controlling subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (hereinafter referred to as "Zhongsheng Ruichuang"), recently received the approval letter for the clinical research project review of a class I innovative drug, Andrazeivir Granules (research and development code: ZSP1273 Granules), for the treatment of 2-17 year-old patients with uncomplicated type A influenza from the Clinical Research Ethics Committee of the Beijing Children's Hospital, the leading unit. The II phase clinical trial project is approved to be launched.
Is Guangdong Zhongsheng Pharmaceutical (SZSE:002317) A Risky Investment?
Guangdong Zhongsheng Pharmaceutical: 2024 Interim Performance Forecast
Guangdong Zhongsheng Pharmaceutical (002317.SZ): Takes the compound thrombus series products as a whole for targeted marketing layout.
On July 3rd, Gelonhui reported that Guangdong Zhongsheng Pharmaceutical (002317.SZ) announced in its investor relations activity that based on the development strategy of core products after the national procurement of Chinese patent medicines, the company has made the following three marketing deployments: firstly, based on the original intention of encouraging medical institutions to choose high-quality, clinically recognized and cost-effective drugs selected in the procurement, the company promotes the channel sinking of its core product, compound thrombolytic agent extrinsic, to cover more county-level, grassroots and retail terminals, and strive for more market share. Secondly, the company regards the compound thrombolytic agent series as a whole for targeted marketing layout, through different specifications in various terminals.
Zhongsheng Pharmaceutical's Unit Gets Nod to Market Gastric Protective Drug
No Data